Cyanopyrroles

A method of providing progestational therapy to a mammal in need thereof which comprises administering a progestationally effective amount of a compound having the structure of formula 1:

• 30
• wherein:
• T is or absent;
• R1 and R2 are each, independently, hydrogen, alkyl, or substituted alkyl;
• or
• R1 and R2 are taken together form a ring selected from the group consisting of —CH2(CH2)nCH2—, —CH2CH2C(CH3)2CH2CH2—, —O(CH2)pCH2—, —O(CH2)qO—, —CH2CH2OCH2CH2—, and —CH2CH2NR7CH2CH2—;
• n=1-5;
• p=1-4;
• q 1-4
• R3 is hydrogen, OH, NH2, alkyl, substituted alkyl, alkenyl, substituted alkenyl, alkynyl, substituted alkynyl, or CORA;
• RA is hydrogen, alkyl, substituted alkyl, alkoxy, substituted alkoxy, aminoalkyl, or substituted aminoalkyl;
• R4 is hydrogen, halogen, CN, NH2, alkyl, substituted alkyl, alkoxy, substituted alkoxy, aminoalkyl, or substituted aminoalkyl;
• R5 is hydrogen, alkyl, or substituted alkyl;
• R6 is hydrogen, alkyl, substituted alkyl, or CORB;
• RB is hydrogen, alkyl, substituted alkyl, alkoxy, substituted alkoxy, aminoalkyl, or substituted aminoalkyl,
• R7 is hydrogen or alkyl;
• or a pharmaceutically acceptable salt thereof, to said mammal.

A method of treating or inhibiting breast, uterine, ovarian, endometrial, or prostate cancer which comprises administering a compound having the structure of formula 1:

• 31
• wherein:
• T is O, S, or absent;
• R1 and R2 are each, independently, hydrogen, alkyl, or substituted alkyl;
• or
• R1 and R2 are taken together form a ring selected from the group consisting of —CH2(CH2)nCH2—, —CH2CH2CMe2CH2CH2—, —O(CH2)pCH2—, —O(CH2)qO—, —CH2CH2OCH2CH2—, and —CH2CH2NR7CH2CH2—;
• n 1-5;
• p=1-4;
• q=1-4;
• R3 is hydrogen, OH, NH2, alkyl, substituted alkyl, alkenyl, substituted alkenyl, alkynyl, substituted alkynyl, or CORA;
• RA is hydrogen, alkyl, substituted alkyl, alkoxy, substituted alkoxy, aminoalkyl, or substituted aminoalkyl;
• R4 is hydrogen, halogen, CN, NH2, alkyl, substituted alkyl, alkoxy, substituted alkoxy, aminoalkyl, or substituted aminoalkyl;
• R5 is hydrogen, alkyl, or substituted alkyl;
• R6 is hydrogen, alkyl, substituted alkyl, or CORB;
• RB is hydrogen, alkyl, substituted alkyl, alkoxy, substituted alkoxy, aminoalkyl, or substituted aminoalkyl;
• R7 is hydrogen or alkyl;
• or a pharmaceutically acceptable salt thereof, to said mammal.

A method of providing contraception in a mammal in need thereof, which comprises administering an effective amount of a compound having the structure of formula 1:

• 32
• wherein:
• T is O or S;
• R1 and R2 are each, independently, hydrogen, alkyl, or substituted alkyl;
• or R1 and R2 are taken together form a selected from the group consisting of —CH2(CH2)nCH2—, —CH2CH2C(CH3)2CH2CH2—, —O(CH2)pCH2—, —O(CH2)qO—, —CH2CH2OCH2CH2—, and —CH2CH2NR7CH2CH2—;
• n=1-5;
• p=1-4;
• q=1-4;
• R3 is hydrogen, OH, NH2, alkyl, substituted alkyl, alkenyl, substituted alkenyl, alkynyl, substituted alkynyl, or CORA;
• RA is hydrogen, alkyl, substituted alkyl, alkoxy, substituted alkoxy, aminoalkyl, or substituted aminoalkyl;
• R4 is hydrogen, halogen, CN, NH2, alkyl, substituted alkyl, alkoxy, substituted alkoxy, aminoalkyl, or substituted aminoalkyl;
• R5 is hydrogen, alkyl, or substituted alkyl;
• R6 is hydrogen, alkyl, substituted alkyl, or CORB;
• RB is hydrogen, alkyl, substituted alkyl, alkoxy, substituted alkoxy, aminoalkyl, or substituted aminoalkyl;
• R7 is hydrogen or alkyl;
• or a pharmaceutically acceptable salt thereof, to said mammal.

A pharmaceutical composition, which comprises a compound having the structure of formula 1:

• 33
• wherein:
• T is S;
• R1 and R2 are each, independently, hydrogen, alkyl, or substituted alkyl;
• or R1 and R2 are taken together form a ring selected from the group consisting of —CH2(CH2)nCH2—, —CH2CH2C(CH3)2CH2CH2—, —O(CH2)pCH2—, —O(CH2)qO—, —CH2CH2OCH2CH2—, and —CH2CH2NR7CH2CH2—;
• n=1-5;
• p=1-4;
• q=1-4;
• R3 is hydrogen, OH, NH2, alkyl, substituted alkyl, alkenyl, substituted alkenyl, alkynyl, substituted alkynyl, or CORA;
• RA is hydrogen, alkyl, substituted alkyl, alkoxy, substituted alkoxy, aminoalkyl, or substituted aminoalkyl;
• R4 is hydrogen, halogen, CN, NH2, alkyl, substituted alkyl, alkoxy, substituted alkoxy, aminoalkyl, or substituted aminoalkyl;
• R5 is hydrogen, alkyl, or substituted alkyl;
• R6 is hydrogen, alkyl, substituted alkyl, or CORB;
• RB is hydrogen, alkyl, substituted alkyl, alkoxy, substituted alkoxy, aminoalkyl, or substituted aminoalkyl;
• R7 is hydrogen or alkyl;
• or a pharmaceutically acceptable salt thereof and a pharmaceutical carrier.

A method of providing hormone replacement therapy to a mammal in need thereof, which comprises administering an effective amount of a compound having the structure of formula 1:

• 34
• wherein:
• T is O, S, or absent;
• R1 and R2 are each, independently, hydrogen, alkyl, or substituted alkyl;
• or R1 and R2 are taken together form a ring selected from the group consisting of —CH2(CH2)nCH2—, —CH2CH2C(CH3)2CH2CH2—, —O(CH2)pCH2—, —O(CH2)qO—, —CH2CH2OCH2CH2—, and —CH2CH2NR7CH2CH2—;
• n=1-5;
• p=1-4;
• q=1-4;
• R3 is hydrogen, OH, NH2, alkyl, substituted alkyl, alkenyl, substituted alkenyl, alkynyl, substituted alkynyl, or CORA;
• RA is hydrogen, alkyl, substituted alkyl, alkoxy, substituted alkoxy, aminoalkyl, or substituted aminoalkyl;
• R4 is hydrogen, halogen, CN, NH2, alkyl, substituted alkyl, alkoxy, substituted alkoxy, aminoalkyl, or substituted aminoalkyl;
• R5 is hydrogen, alkyl, or substituted alkyl;
• R6 is hydrogen, alkyl, substituted alkyl, or CORB;
• RB is hydrogen, alkyl, substituted alkyl, alkoxy, substituted alkoxy, aminoalkyl, or substituted aminoalkyl;
• R7 is hydrogen or alkyl;
• or a pharmaceutically acceptable salt thereof, to said mammal.